Please share what your organisation and Boehringer Ingelheim will Co-Create together
Enhancing Patient Safety through better infection prevention and control capacity building and healthcare compliance.
The digital platform for building competencies as well as improving healthcare compliance can also be used to explore the link between competency, health practice and health outcomes underpinned by GIS data. Building on the potential of such analytics would be a key outcome for the collaboration.
This is one of the key opportunities opened up by the 'digital healthcare' opportunity.
Initiatives such as mPESA (in mobile banking) in East Africa show how digital opportunities can be as significant in emerging markets as they are in more mature, developed markets.
If you selected "other" above, please explain:
Insights into digital health.
Please provide a 1-2 sentence summary of your Co-Creation idea
Improve infection prevention and control as well as patient safety by further development of, and scaling the ebuddi model - an interactive and intuitive simulation based training underpinned by powerful analytics, that has been developed to train community health workers in response to the Ebola crisis in West Africa.
How does this project link to the core mission of your organisation?
MiiHealth Ltd was created to catalyse a transformation in IPC training, through applying technology enhanced learning to improve knowledge retention, confidence and ultimately competence – and to make quality assured training accessible worldwide.
This project would mark a move beyond Ebola related training and West Africa to show how the platform developed and insights gained have a relevance to healthcare across the globe. The massive investment in pharmaceuticals and other healthcare technologies will only lead to improved health outcomes if there is an associated advance in the competencies of healthcare workers and carers to be able able to use them properly and minimise the risk of opportunistic infections. We will use this project to mark a new phase of development and application of the ebuddi system.
Beyond social impact, how does this project link to Boehringer Ingelheim’s core business?
Patient welfare and safety is at the heart of BI's human health business, and infection prevention and control is a theme that underpins both human and veterinary care.
However we think there are broader, more strategic reasons why the MiiHealth Initiative could be of strategic importance to BI.
In the McKinsey article ‘How pharma can win in a digital world’ McKinsey consultants spoke to 20 leading executives to find out how they cope—and what they do to stay ahead. The backdrop to this research was that in 2014, digital health investments topped $6.5 billion, compared with $2.9 billion a year earlier.
The sheer scale of this investment raises the question for pharmaceutical companies as to how to ensure their investments leverage existing insights and open up new opportunities for adding value to their health solutions.
The article highlighted the fact that there is a consensus that: ‘as healthcare continues to digitize, pharma companies must transform themselves in basic ways to stay competitive. Successful ones will rethink their business and operating models, transform their cultures and capabilities, and adopt a new, longer-term mind-set that fosters innovation and bold strategic moves.
The article concluded that winning will involve ‘developing a collaborative culture and challenging barriers to sharing, and reinventing companies by building capabilities beyond traditional healthcare and updating the operating model.’
A co-creation project with MiiHealth could be of strategic value in 3 main ways:
1) Adding value to the service proposition and improving health outcomes
Dr. Krishna Yeshwant of Google Ventures pinpoints the challenge in this potential future: “For pharma, there comes the question of whether they can tie digital to the assets they have. There is an interesting broader conversation to have with pharmacos about moving from a products-and-pills company to a solutions company.”
The associate director of US medical affairs of a global pharma company commented “One of the most exciting values of digital to the pharmaceutical industry is how technology may be able to supplement or support pharmacological therapies to more effectively address the problem of suboptimal outcomes.”
This latter point is exactly where MiiHealth could help, tying in data on competence and compliance to health outcomes. Because the training can be provided on tablets, there is the potential to link competence with GIS data which can then be linked through to health outcomes. This opportunity to link health outcomes to GIS data through to compliance and competence could be as significant as the use of health economics data to improve the cost effectiveness of clinical practice.
This is based on almost 30 years of insights involving health economics which started in 1987 when I led a collaboration with Prof Alan Maynard at York University for Smith Kline to look at the cost effectiveness of different vaccine strategies. This became one of the pioneering studies within the pharmaceutical industry on health economics.
2) As a tool for empowering the carer within health and social care
This recognises that where healthcare takes place is changing. As BI UK pointed out in their White paper ‘Empowering the carer within health and social care’ what the NHS needs to deliver to survive as a 21st century institution, includes taking care out of the hospital and back into the community, wherever possible. This will require giving the families and carers the knowledge, confidence and competence to care effectively and keep their patient, themselves and the rest of the family safe. This is true for most markets – not just in the UK.
3) Emerging markets – drivers of growth
The McKinsey Insight article ‘Africa: A continent of opportunity for pharma and patients’ concludes: ‘In a world of slowing and stagnating markets, Africa represents the last geographic frontier where high growth is still achievable. As ever, the key to success lies in understanding individual markets in granular detail. Early movers with the right approach should be able to capture competitive advantage. Africa will continue to grow for the foreseeable future. Now is the time for drug companies to decide whether they want to be part of that growth and, more important, play an active role in improving public health.’
A key driver of growth has been Healthcare capacity. ‘Between 2005 and 2012, Africa added 70,000 new hospital beds, 16,000 doctors, and 60,000 nurses. Healthcare provision is becoming more efficient through initiatives such as Mozambique’s switch to specialist nurse anaesthetists and South Africa’s use of nurses to initiate antiretroviral drug therapy. The introduction of innovative delivery models is increasing capacity still further.’
Building local capacity and ensuring compliance in the use of pharmaceuticals is key to growing, sustaining market development and market leadership in these fiercely competitive emerging markets.
The 2014 McKinsey article Healthcare’s digital future concluded:
‘Digitally enabled healthcare is here, and most pharmaceutical companies aren’t ready. Despite access to unprecedented data and technologies that can be used to drive better health outcomes by influencing customer behavior, few are truly exploring digital-engagement models. The opportunity to learn more about consumers and develop better, more targeted products and services far outweighs the threat digitization presents companies—for now. Unless incumbent pharmaceutical companies move quickly, innovative competitors may grab a greater share of benefits and stronger customer loyalty.’
What are the specific inputs and actions that each side will contribute to this Co-Creation idea based on each of your unique competencies and experiences?
My organization will contribute:
Prototype platform / product which has been developed for West Africa for training and assessing compliance.
Global health network with International organisations and policy makers
Potential insight into the learning journey through the ebuddi analytics, as well as broader insights into innovation and digital health
Boehringer Ingelheim may be able to contribute:
Its own insights into healthcare compliance and patient / carer centric care
Investment in the service
lessons learnt from virtual veterinary academy and its other digital health initiatives.
Support with competency evaluation and building evidence base around improved patient safety outcomes
Please describe the potential revenue model for this Co-Creation idea.
Fee for service based on use of the training module as well as 'contextualised performance support' .
Insights into the training programme can be derived from analysis of the data profile from the individual learner as well as training programme.
As the data set grows with time and scale, the analytics will provide ever greater insight and scope for adding value to the customer (be they in the public or private sector).
What possible risks or challenges do you foresee?
Ensuring appropriate contextualisation of the learning material
Ensuring an appropriate balance between maximising access to ebuddi as a training tool for frontline workers in low income countries as well as generating revenue from wealthier countries - not unlike the challenge around anti retroviral therapy.
Responding to the need to enable the training to be accessible on a specified tablet to a 'Bring your own device model'
Is there anything else you would like to share about your Co-Creation idea?
We have interest in our approach from health agencies in:
- the US (agencies addressing the challenge of health security and outbreak response
- Europe (EU DG Sante and the European CDC), as well as expressions of interest from a number of healthcare Ministers,
Our specific is global and the team has already been involved in initiatives which have sought to reshape the global health agenda
If you selected "other" above, please explain:
Besides Boehringer Ingelheim, what other types of partners might be valuable to carrying out your Co-Creation idea, and why?
Agencies involved in global health policy and practice - with a particular concern about infection prevention and patient safety. These include:
Public Health England
Department of Health
WHO Patient Safety Group
ECDC (European Centre for Disease Control)
EU DG Sante